» Articles » PMID: 1233077

Cellular Immunocompetence in Melanoma: Effect of Extent of Disease and Immunotherapy

Overview
Journal Br J Cancer
Specialty Oncology
Date 1975 Sep 1
PMID 1233077
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Cell mediated immunocompetence was measured serially in 35 patients with malignant melanoma in order to determine the effect of extent of disease and prognosis as well as the influence of BCG immunotherapy on immune reactivity. Compared with normal adult controls, statistically significant lymphopenia occurred only in patients with widespread disease. Seventeen of 21 patients with negative pre-therapy PPD skin test converted to skin test positivity. PHA blastogenesis was depressed only in patients in the pre-terminal stages of their disease using optimal mitogen concentrations for stimulation. Threshold concentrations of this mitogen more clearly demonstrated a depressed responsiveness which correlated in severity with extent of disease. PPD induced blastogenesis was normal or increased in the majority of patients; however, the degree of stimulation by PPD was less in the BCG induced convertors than in those patients who were skin test positive before BCG treatment. Comparison of the pre- and post BCG assessments reveals no significant differences except in relation to PPD conversion. We conclude that using threshold concentrations of PHA, impaired responses are regularly associated with disease beyond the regional lymph nodes. Routine assessment of lymphocyte function by these parameters did not provide information that was not available from clinical evaluation.

Citing Articles

Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies.

Chen Y, Qi F, Sun C, Jiang P, Xue X, Yang X Ther Adv Med Oncol. 2025; 17():17588359241312501.

PMID: 39781239 PMC: 11707791. DOI: 10.1177/17588359241312501.


[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].

Qi C, Tian P, Li W Zhongguo Fei Ai Za Zhi. 2024; 27(2):138-146.

PMID: 38453446 PMC: 10918244. DOI: 10.3779/j.issn.1009-3419.2024.102.06.


Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.

Hoefsmit E, Vollmy F, Rozeman E, Reijers I, Versluis J, Hoekman L Cancer Res Commun. 2023; 3(4):672-683.

PMID: 37089863 PMC: 10117404. DOI: 10.1158/2767-9764.CRC-23-0015.


Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.

Ferraresi V, Vari S Hum Vaccin Immunother. 2021; 18(3):1971015.

PMID: 34882516 PMC: 9122306. DOI: 10.1080/21645515.2021.1971015.


Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?.

Ahern E, Solomon B, Hui R, Pavlakis N, OByrne K, Hughes B J Immunother Cancer. 2021; 9(6).

PMID: 34083418 PMC: 8183290. DOI: 10.1136/jitc-2020-002248.


References
1.
Ziegler J, Lewis M, Luyombya J, Kiryabwire J . Immunologic studies in patients with malignant melanoma in Uganda. Br J Cancer. 1969; 23(4):729-34. PMC: 2008492. DOI: 10.1038/bjc.1969.89. View

2.
Oppenheim J, Leventhal B, Hersh E . The transformation of column-purified lymphocytes with nonspecific and specific antigenic stimuli. J Immunol. 1968; 101(2):262-7. View

3.
Golub S, OConnell T, Morton D . Correlation of in vivo and in vitro assays of immunocompetence in cancer patients. Cancer Res. 1974; 34(8):1833-7. View

4.
Greene W, Schimpff S, Wiernik P . Cell-mediated immunity in acute nonlymphocytic leukemia: relationship to host factors, therapy, and prognosis. Blood. 1974; 43(1):1-14. View

5.
Harris J, Copeland D . Impaired immunoresponsiveness in tumor patients. Ann N Y Acad Sci. 1974; 230:56-85. DOI: 10.1111/j.1749-6632.1974.tb14437.x. View